Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model
| Autor: | Xin-Yue Guo, Yan-Yan Zhang, Javad Rasouli, Xing Li, Abdolmohamad Rostami, Su-Min Ye, Lin Zhu, Li-Bin Wang, Wen-Cheng Wu, Ze-Qing Ye, Yun Xiao, Yuan Zhang, Bing Han |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cyclopropanes
Encephalomyelitis Autoimmune Experimental Multiple Sclerosis Immunology Anti-Inflammatory Agents Inflammation Acetates Sulfides Mice immune system diseases In vivo medicine Animals Humans Immunology and Allergy Molecular Targeted Therapy Receptor Montelukast Receptors Leukotriene Leukotriene receptor business.industry Multiple sclerosis Experimental autoimmune encephalomyelitis Cell Differentiation Chemotaxis Original Articles medicine.disease Adoptive Transfer Mice Inbred C57BL Disease Models Animal Quinolines Leukotriene Antagonists Th17 Cells Female medicine.symptom business Signal Transduction medicine.drug |
| Zdroj: | Immunology |
| ISSN: | 1365-2567 0019-2805 |
| DOI: | 10.1111/imm.13308 |
| Popis: | Montelukast is a leukotriene receptor antagonist that is known to prevent allergic rhinitis and asthma. Blocking the Cysteinyl leukotriene receptor (CysLTR1), one of the primary receptors of leukotrienes, has been demonstrated to be efficacious in ameliorating experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), through disrupting chemotaxis of infiltrating T cells. However, the role of CysLTR1 in the pathogenesis of MS is not well understood. Here, we show that MS patients had higher expression of CysLTR1 in the circulation and central nervous system (CNS). The majority of CD4(+) T cells expressed CysLTR1 in MS lesions. Among T‐cell subsets, Th17 cells had the highest expression of CysLTR1, and blocking CysLTR1 signalling abrogated their development in vitro. Inhibition of CysLTR1 by montelukast suppressed EAE development in both a prophylactic and therapeutic manner and inhibited myelin loss in EAE mice. Similarly, the in vivo results showed that montelukast inhibited Th17 response in EAE mice and that Th17 cells treated with montelukast had reduced encephalitogenic in adoptive EAE. Our findings strongly suggest that targeting Th17 response by inhibiting CysLTR1 signalling could be a promising therapeutic strategy for the treatment of MS and CNS inflammatory diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|